James Raftery: NICE, obesity, and bariatric surgery
The trends on obesity are shocking. UK data on the prevalence of obesity in adults and children are provided by the National Obesity Observatory, which also shows the social gradient […]
Search Results for: james raftery NICE
James Raftery: The NHS top-up policy for drugs not recommended by NICE – challenging the limits?
A recent breakfast meeting at the Kings Fund discussed the issue of an NHS top-up policy in relation to multifocal lenses in cataract surgery. My contribution from the commissioner perspective […]
James Raftery: Avastin, Lucentis, and NICE
A useful update was provided at a meeting this week sponsored by the Royal National Institute for the Blind (RNIB) and Patients Involved in NICE (the National Institute for Health […]
James Raftery: What does “value based pricing” mean for NICE?
The “value based pricing” consultation paper” makes the following relevant references to the future of the National Institute for Health and Clinical Excellence (NICE). […]
James Raftery: What’s happening with NICE? The cancer drugs fund and “value based pricing”
The reports that NICE is to be stripped of its powers to recommend against NHS use of drugs prompts questions about the Coalition Government’s health plans. Some indication of what […]
James Raftery: NICE changes its position on Alzheimer’s disease drugs
The provisional guidance from NICE on drugs for Alzheimers’ disease – donepezil, galantamine, rivastigmine, and memantine – marks a dramatic shift from restricting access to those with moderate disease to […]
James Raftery: NICE – the beginning of the end—or a new beginning?
The coalition programme for government states: “We will create a cancer drugs fund to enable patients to access the cancer drugs their doctors think will help them, paid for using […]
James Raftery: Bypassing NICE for the sake of innovation?
Recent reports that NICE was to be bypassed by drugs which were “innovative,” with funding from a new separate budget, sent me in search of the source report – the […]
James Raftery: The judicial review of NICE’s appraisal of drugs for secondary treatment of osteoporosis
The report of this judgment made me laugh out loud several times. Mr Justice Holman twice describes proceedings as “bizarre”. A key confidentiality agreement with Dr Kanis could not be […]
James Raftery on NICE’s cost per QALY threshold: does the public have a view?
One approach to setting NICE’s cost per QALY threshold might be to survey the public. In 2003 NICE and the Department of Health did just that, with a study “assessing […]